Peer-Reviewed Research
TB-500 is commonly discussed in connection with thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide involved in actin regulation, cell migration, inflammation, angiogenesis, and tissue-repair pathways. Most peer-reviewed research has evaluated full-length Tβ4 rather than TB-500 as a distinct research compound. The publications below should therefore be presented as thymosin beta-4 research relevant to the scientific background of TB-500, not as direct clinical evidence for the TB-500 product itself.
Original Research
In Vitro Study of Thymosin Beta 4 Promoting Transplanted Fat Survival
Published: 2024
Study Type: Original laboratory and preclinical research
Summary
This study evaluated thymosin beta-4 in models involving transplanted adipose tissue. Researchers examined fat-graft survival, cellular activity, angiogenesis-related pathways, and wound-healing behavior. The findings supported further investigation of Tβ4 in tissue-regeneration and graft-survival research. This publication studied thymosin beta-4 rather than TB-500 as a separate compound.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/38409346/
Activation of pro-resolving pathways mediate the therapeutic effects of thymosin beta 4 in bacterial keratitis
Published: 2024
Study Type: Original laboratory and preclinical research
Summary
Researchers investigated thymosin beta-4 in experimental bacterial keratitis. The study reported activation of specialized pro-resolving mediator pathways, increased macrophage phagocytosis, and improved resolution of inflammation and tissue repair in corneal models. These findings relate specifically to Tβ4 and ocular inflammatory research.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/39380984/
Injectable Thymosin β4-Modified Hyaluronic Acid Hydrogel with BMSC-Derived Exosomes for Enhanced Bone Regeneration through Neurovascularization
Published: 2025
Study Type: Original laboratory and preclinical biomaterials research
Summary
This study developed an injectable hydrogel containing thymosin beta-4 and bone-marrow stem-cell-derived extracellular vesicles. In experimental models, the platform promoted stem-cell recruitment, angiogenesis, neurogenesis, and new bone formation. Because Tβ4 was incorporated into a combined biomaterial system, the findings should not be attributed to Tβ4 alone.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/40528381/
Tβ4-Engineered ADSC Extracellular Vesicles Rescue Cell Survival and Promote Angiogenesis Under Ischemic Conditions
Published: 2025
Study Type: Original laboratory and preclinical research
Summary
Researchers engineered extracellular vesicles from adipose-derived stem cells to express thymosin beta-4. The modified vesicles were studied for their effects on cell survival, vascular signaling, and tissue recovery under ischemic conditions. This publication evaluated an engineered Tβ4 delivery system rather than TB-500 itself.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/40279568/
Recent Review and Mechanistic Research
Thymosin β4 and the anti-fibrotic switch
Published: 2023
Study Type: Scientific review
Summary
This review discusses experimental evidence involving thymosin beta-4 in fibrosis and scar formation. It examines pathways associated with myofibroblast activity, extracellular-matrix remodeling, inflammation, and tissue repair across several preclinical disease models.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/36580759/
Thymosin β4 and Actin: Binding Modes, Biological Functions and Clinical Applications
Published: 2023
Study Type: Mechanistic scientific review
Summary
This publication reviews thymosin beta-4’s interaction with actin and its roles in cell migration, inflammation, angiogenesis, wound healing, regeneration, and disease biology. It provides useful mechanistic background for understanding why Tβ4-related compounds are investigated in tissue-repair research.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/36464872/
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Published: 2026
Study Type: Clinical and scientific review
Summary
This review discusses investigational injectable peptides used in orthopedic and sports-medicine settings. It distinguishes thymosin beta-4 and its derivatives from established therapies and notes that preclinical evidence suggests roles in angiogenesis and tissue repair, while direct human orthopedic evidence remains limited.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/41476424/
Additional Thymosin Beta-4 Publications
Browse current PubMed research:
https://pubmed.ncbi.nlm.nih.gov/?term=%22thymosin+beta+4%22
Research Disclaimer
The information presented in this Research Library is provided for educational and scientific reference purposes only and is based on published peer-reviewed research. Research findings continue to evolve, and investigational compounds may not be approved for clinical use. All Pearland Peptides products are supplied For Research Use Only and are not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease.